GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Synonyms: JNJ-2113 | JNJ-77242113 | JNJ77242113
Compound class:
Peptide
Comment: Icotrokinra (JNJ-77242113) is an oral IL-23 receptor peptide inhibitor (antagonist) [1-2].
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use ![]() |
JNJ-77242113 is being evaluated for safety and efficacy as a therapeutic for inflammatory autoimmune conditions, including psoriasis and ulcerative colitis. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT05223868 | A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque Psoriasis | Phase 2 Interventional | Janssen Research & Development, LLC | 1 | |
NCT06049017 | A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis | Phase 2 Interventional | Janssen Research & Development, LLC | ||
NCT06934226 | A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis | Phase 3 Interventional | Janssen Research & Development, LLC | ||
NCT06878404 | A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis | Phase 3 Interventional | Janssen Research & Development, LLC | ||
NCT06807424 | A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced Participants With Active Psoriatic Arthritis | Phase 3 Interventional | Janssen Research & Development, LLC |